In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro.

Publication date: Jun 18, 2024

Neurodegenerative disorders are typically featured by the occurrence of neuronal inclusions. In the case of Parkinson’s disease (PD) these correspond to Lewy bodies (LBs), which are routinely defined as proteinaceous inclusions composed of alpha-synuclein (alpha-syn). In turn, alpha-syn is considered to be the key protein in producing PD and fostering its progression. Recent studies challenged such a concept and emphasized the occurrence of other proteins such as p62 and poly-ubiquitin (Poly-ub) in the composition of LBs, which are also composed of large amounts of tubulo-vesicular structures. All these components, which accumulate within the cytosol of affected neurons in PD, may be the consequence of a dysfunction of major clearing pathways. In fact, autophagy-related systems are constantly impaired in inherited PD and genetic models of PD. The present study was designed to validate whether a pharmacological inhibition of autophagy within catecholamine cells produces cell damage and accumulation of specific proteins and tubulo-vesicular structures. The stoichiometry counts of single proteins, which accumulate within catecholamine neurons was carried out along with the area of tubulo-vesicular structures. In these experimental conditions p62 and Poly-ub accumulation exceeded at large the amounts of alpha-syn. In those areas where Poly-ub and p62 were highly expressed, tubulo-vesicular structures were highly represented compared with surrounding cytosol. The present study confirms new vistas about LBs composition and lends substance to the scenario that autophagy inhibition rather than a single protein dysfunction as key determinant of PD.

Open Access PDF

Concepts Keywords
Constantly Autophagosome
Neurodegenerative Autophagy
Proteinaceous Lewy bodies
Ubiquitin Poly-ubiquitin
Vienna Proteasome
Sequestosome

Semantics

Type Source Name
pathway KEGG Autophagy
disease MESH Neurodegenerative disorders
disease MESH Parkinson’s disease
pathway KEGG Proteasome
drug DRUGBANK Flunarizine
disease MESH Dementia
drug DRUGBANK Gold
disease MESH experimental parkinsonism
disease MESH death
drug DRUGBANK Dopamine
drug DRUGBANK Tretamine
disease MESH Pheochromocytoma
drug DRUGBANK Streptomycin
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK L-Lysine
drug DRUGBANK Water
drug DRUGBANK Ethanol
drug DRUGBANK Potassium permanganate
drug DRUGBANK Acetic acid
drug DRUGBANK Acetate ion
drug DRUGBANK Amino acids
disease MESH eosinophilia

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *